English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To the Editor, We would like to thank Balbuena-Merle and colleagues [1] for their interest in our study of red blood cell (RBC) alloimmunization in Korean patients with myelodysplastic syndrome (MDS) and liver cirrhosis (LC) [2]. There is a high prevalence of sickle cell disease (SCD) in Africa, the Middle East, India, parts of the Mediterranean, and Puerto Rico, and high rates of RBC alloimmunization in SCD patients have been reported in these regions [3]. In contrast, SCD is extremely rare in Korea, and alloimmunization in SCD patients has never been documented. The frequencies of C, c, E, e, Fy, Jk, M, and K antigens differ across races. The K antigen is particularly important as it has high immunogenicity; however, the frequencies of the K antigen and the anti-K alloantibody are extremely low in the Korean and other South East Asian (i.e., Chinese and Japanese) populations, unlike in European and Caucasian populations [4, 5]. With respect to the transfusion policies, the study by Balbuena-Merle, et al. [1] from Puerto Rico was different from our study in Korea because of the differences in disease prevalence and alloantibody formation. While 91% of pediatric SCD patients SCD received RBCs matched for at least ABO, Rh, and K blood groups (limited RBC matching), none of the patients in our study received RBCs matched for groups other than ABO and RhD (Table 1). However, the overall alloimmunization rate (15.4% [8/52 patients] vs 6.3% [20/317 patients]) was much lower in our study despite the similar amount of transfused RBC units; this was considered to be due to the higher ethnic homogeneity of Koreans than that of Puerto Ricans. Although Balbuena-Merle, et al. [1] described Puerto Ricans as a genetically homogeneous group, their population comprises Caucasians (74.7%), people of African descent (15.3%), and other populations according to the 2013−2017 American Community Survey [6]. We additionally calculated the prevalence of alloantibody formation per transfusion events. After transfusion of 5,886 RBC units, the formation of 29 alloantibodies was recorded, and the prevalence of alloantibody formation per transfusion event was 0.49 alloantibodies per 100 units. Among the disease groups, the prevalence of alloantibody formation per transfusion event was the highest in the LC group (1.13 per 100 units), followed by the MDS group (0.22 per 100 units), and the prevalence among Puerto Rican patients was 3 per 100 units. In our study, the most common alloantibody was that against

Extended Red Blood Cell Phenotype Matching Is Dependent on Ethnicity and Specificity of RBC Alloantibodies